144 related articles for article (PubMed ID: 22335591)
1. Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma.
Ikenberg K; Pfaltz M; Rakozy C; Kempf W
J Cutan Pathol; 2012 Mar; 39(3):324-30. PubMed ID: 22335591
[TBL] [Abstract][Full Text] [Related]
2. Useof anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma.
Casper DJ; Ross KI; Messina JL; Sondak VK; Bodden CN; McCardle TW; Glass LF
Am J Dermatopathol; 2010 Oct; 32(7):650-4. PubMed ID: 20559123
[TBL] [Abstract][Full Text] [Related]
3. Detection of mitotic figures in thin melanomas--immunohistochemistry does not replace the careful search for mitotic figures in hematoxylin-eosin stain.
Ottmann K; Tronnier M; Mitteldorf C
J Am Acad Dermatol; 2015 Oct; 73(4):637-44. PubMed ID: 26278815
[TBL] [Abstract][Full Text] [Related]
4. pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas.
Schimming TT; Grabellus F; Roner M; Pechlivanis S; Sucker A; Bielefeld N; Moll I; Schadendorf D; Hillen U
Am J Dermatopathol; 2012 May; 34(3):266-9. PubMed ID: 22197861
[TBL] [Abstract][Full Text] [Related]
5. Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
J Invest Dermatol; 2012 Apr; 132(4):1247-52. PubMed ID: 22297638
[TBL] [Abstract][Full Text] [Related]
6. Differences in tumor thickness between hematoxylin and eosin and Melan-A immunohistochemically stained primary cutaneous melanomas.
Drabeni M; Lopez-Vilaró L; Barranco C; Trevisan G; Gallardo F; Pujol RM
Am J Dermatopathol; 2013 Feb; 35(1):56-63. PubMed ID: 22688397
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases.
Fukushima S; Terasaki M; Sakata K; Miyagi N; Kato S; Sugita Y; Shigemori M
Brain Tumor Pathol; 2009; 26(2):51-7. PubMed ID: 19856215
[TBL] [Abstract][Full Text] [Related]
8. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical assessment of mitotic count in uveal melanoma.
Angi M; Damato B; Kalirai H; Dodson A; Taktak A; Coupland SE
Acta Ophthalmol; 2011 Mar; 89(2):e155-60. PubMed ID: 19900200
[TBL] [Abstract][Full Text] [Related]
10. Frequent mitotic activity in banal melanocytic nevi uncovered by immunohistochemical analysis.
Glatz K; Hartmann C; Antic M; Kutzner H
Am J Dermatopathol; 2010 Oct; 32(7):643-9. PubMed ID: 20661119
[TBL] [Abstract][Full Text] [Related]
11. Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma.
Tetzlaff MT; Curry JL; Ivan D; Wang WL; Torres-Cabala CA; Bassett RL; Valencia KM; McLemore MS; Ross MI; Prieto VG
Mod Pathol; 2013 Sep; 26(9):1153-60. PubMed ID: 23558574
[TBL] [Abstract][Full Text] [Related]
12. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas.
Colman H; Giannini C; Huang L; Gonzalez J; Hess K; Bruner J; Fuller G; Langford L; Pelloski C; Aaron J; Burger P; Aldape K
Am J Surg Pathol; 2006 May; 30(5):657-64. PubMed ID: 16699322
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
14. Phosphohistone H3 expression correlates with manual mitotic counts and aids in identification of "hot spots" in fibroepithelial tumors of the breast.
Ginter PS; Shin SJ; Liu Y; Chen Z; D'Alfonso TM
Hum Pathol; 2016 Mar; 49():90-8. PubMed ID: 26826415
[TBL] [Abstract][Full Text] [Related]
15. Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Schmidt H; Steiniche T
Diagn Pathol; 2016 Apr; 11():35. PubMed ID: 27062658
[TBL] [Abstract][Full Text] [Related]
16. Does mitosis-specific marker phosphohistone H3 help the grading of upper tract urothelial carcinomas in cell blocks?
Solomides CC; Birbe RC; Nicolaou N; Bagley D; Bibbo M
Acta Cytol; 2012; 56(3):285-8. PubMed ID: 22555531
[TBL] [Abstract][Full Text] [Related]
17. Phosphohistone-H3 and Ki-67 immunostaining in cutaneous pilar leiomyoma and leiomyosarcoma (atypical intradermal smooth muscle neoplasm).
Idriss MH; Kazlouskaya V; Malhotra S; Andres C; Elston DM
J Cutan Pathol; 2013 Jun; 40(6):557-63. PubMed ID: 23550775
[TBL] [Abstract][Full Text] [Related]
18. Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.
Duregon E; Cassenti A; Pittaro A; Ventura L; Senetta R; Rudà R; Cassoni P
Neuro Oncol; 2015 May; 17(5):663-9. PubMed ID: 25646026
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas.
Kim YJ; Ketter R; Steudel WI; Feiden W
Am J Clin Pathol; 2007 Jul; 128(1):118-25. PubMed ID: 17580279
[TBL] [Abstract][Full Text] [Related]
20. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
